T. Rowe Price Associates
AMED

T. Rowe Price Associates’s Amedisys AMED Stock Holding History

T. Rowe Price Associates’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,340
Closed -$2M – 3046
2025
Q2 		$2M Buy
20,340
+563
+3% +$53.3K ﹤0.01% 1635
2025
Q1 		$1.83M Buy
19,777
+1,481
+8% +$137K ﹤0.01% 1646
2024
Q4 		$1.66M Buy
18,296
+1,625
+10% +$149K ﹤0.01% 1731
2024
Q3 		$1.61M Buy
16,671
+256
+2% +$25K ﹤0.01% 1742
2024
Q2 		$1.51M Sell
16,415
-14,784
-47% -$1.37M ﹤0.01% 1699
2024
Q1 		$2.88M Buy
31,199
+255
+0.8% +$23.9K ﹤0.01% 1408
2023
Q4 		$2.94M Sell
30,944
-4,186
-12% -$391K ﹤0.01% 1381
2023
Q3 		$3.28M Sell
35,130
-193,051
-85% -$17.8M ﹤0.01% 1299
2023
Q2 		$20.9M Sell
228,181
-21,982
-9% -$1.8M ﹤0.01% 928
2023
Q1 		$18.4M Sell
250,163
-22,766
-8% -$1.97M ﹤0.01% 938
2022
Q4 		$22.8M Sell
272,929
-73,274
-21% -$6.61M ﹤0.01% 874
2022
Q3 		$33.5M Sell
346,203
-400,065
-54% -$47.7M 0.01% 759
2022
Q2 		$78.4M Sell
746,268
-168,412
-18% -$21.5M 0.01% 732
2022
Q1 		$158M Sell
914,680
-327,766
-26% -$49M 0.02% 601
2021
Q4 		$201M Sell
1,242,446
-29,940
-2% -$4.81M 0.02% 554
2021
Q3 		$190M Sell
1,272,386
-211,615
-14% -$44M 0.02% 562
2021
Q2 		$363M Sell
1,484,001
-59,893
-4% -$15.7M 0.03% 410
2021
Q1 		$409M Sell
1,543,894
-16,563
-1% -$4.67M 0.04% 373
2020
Q4 		$458M Buy
1,560,457
+52,343
+3% +$13.4M 0.05% 339
2020
Q3 		$357M Sell
1,508,114
-11,748
-0.8% -$2.67M 0.04% 358
2020
Q2 		$302M Sell
1,519,862
-33,891
-2% -$6.32M 0.04% 382
2020
Q1 		$285M Sell
1,553,753
-20,869
-1% -$3.71M 0.05% 345
2019
Q4 		$263M Buy
1,574,622
+83,024
+6% +$12.3M 0.03% 425
2019
Q3 		$195M Buy
1,491,598
+142,193
+11% +$18.5M 0.03% 453
2019
Q2 		$164M Buy
1,349,405
+999,892
+286% +$119M 0.02% 512
2019
Q1 		$43.1M Buy
349,513
+55,223
+19% +$6.93M 0.01% 928
2018
Q4 		$34.5M Buy
294,290
+98,118
+50% +$11.6M 0.01% 959
2018
Q3 		$24.5M Buy
196,172
+184,506
+1,582% +$20.4M ﹤0.01% 1159
2018
Q2 		$997K Buy
11,666
+40
+0.3% +$2.94K ﹤0.01% 1841
2018
Q1 		$702K Sell
11,626
-2,244
-16% -$128K ﹤0.01% 1948
2017
Q4 		$731K Sell
13,870
-10
-0.1% -$527 ﹤0.01% 1926
2017
Q3 		$777K Buy
13,880
+1,500
+12% +$79.3K ﹤0.01% 1896
2017
Q2 		$778K Hold
12,380
– – ﹤0.01% 1879
2017
Q1 		$632K Sell
12,380
-3,000
-20% -$143K ﹤0.01% 1973
2016
Q4 		$656K Buy
+15,380
New +$654K ﹤0.01% 1941

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

T. Rowe Price Associates's AMED Position: Q3 2025 in Review

T. Rowe Price Associates sold out of Amedisys (AMED) in Q3 2025, closing a stake of 20,340 shares — an estimated $2M sold.

T. Rowe Price Associates first reported a position in AMED in Q4 2016 and held it in 35 quarters. The position peaked at $458M in Q4 2020. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • T. Rowe Price Associates reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 20,340 Amedisys shares in Q3 2025, an estimated $2M.
  • T. Rowe Price Associates first reported a position in Amedisys in Q4 2016 and held it in 35 quarters.
  • T. Rowe Price Associates's Amedisys position peaked at $458M in Q4 2020.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on T. Rowe Price Associates's 13F filing for Q3 2025, filed 14 Nov 2025.